| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab169301-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $49.90 | |
| Ab169301-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $207.90 | |
| Ab169301-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $567.90 | |
| Ab169301-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $867.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG2; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Tremelimumab (anti-CTLA-4) - Primary antibody, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to CTLA-4 / CD152, >95%, high purity, Human IgG2, Antibody of cytotoxic T-lymphocyte-associated protein 4 |
|---|---|
| Synonyms | Tremelimumab | Ticilimumab | CP-675 | 206 | ALPS5 antibody | CD 152 antibody | CD antibody | CD152 antibody | CD152 antigen antibody | CD152 isoform antibody | Celiac disease 3 antibody | CELIAC3 antibody | CTLA 4 antibody | CTLA-4 antibody | CTLA4 antibo |
| Specifications & Purity | Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, ≥95%(SDS-PAGE&SEC-HPLC), See COA |
| Host species | Human |
| Specificity | CTLA-4 / CD152 |
| Application | ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | INHIBITOR |
| Mechanism of action | Antibody of cytotoxic T-lymphocyte-associated protein 4 (CD152) |
| Product Description | Tremelimumab is an anti-CTLA-4 monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research. |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | Human IgG2 |
| Light Chain Type | kappa |
| SDS-PAGE | 26.1 kDa (Light Chain) & 52.2 kDa (Heavy Chain), under reducing conditions; 178.0 kDa, under non-reducing conditions. |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | See COA |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle. |
| CAS | 745013-59-6 |
Tremelimumab (anti-CTLA-4) (Ab169301) - ELISA
Immobilized Recombinant Human CTLA-4 Protein at 2 μg/mL can bind Tremelimumab (anti-CTLA-4) (Ab169301) with the EC₅₀ of 4.38 ng/mL.
Tremelimumab (anti-CTLA-4) (Ab169301) - SEC
The purity of Tremelimumab (anti-CTLA-4) (Ab169301) is more than 95% verified by HPLC.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Find and download the COA for your product by matching the lot number on the packaging.
2 results found
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ23F1001509 | Certificate of Analysis | Nov 02, 2023 | Ab169301 |
| ZJ23F1001510 | Certificate of Analysis | Nov 02, 2023 | Ab169301 |
| 1. Reuben JM, Lee BN, Li C, Gomez-Navarro J, Bozon VA, Parker CA, Hernandez IM, Gutierrez C, Lopez-Berestein G, Camacho LH. (2006) Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma.. Cancer, 106 (11): (2437-44). [PMID:16615096] [10.1021/op500134e] |
| 2. Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M et al.. (2015) Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.. Lancet Respir Med, 3 (4): (301-9). [PMID:25819643] [10.1021/op500134e] |
| 3. Joshua AM, Monzon JG, Mihalcioiu C, Hogg D, Smylie M, Cheng T. (2015) A phase 2 study of tremelimumab in patients with advanced uveal melanoma.. Melanoma Res, 25 (4): (342-7). [PMID:26050146] [10.1021/op500134e] |
| 4. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA. (1991) CTLA-4 is a second receptor for the B cell activation antigen B7.. J Exp Med, 174 (3): (561-9). [PMID:1714933] [10.1021/op500134e] |
| 5. Harper, K K and 5 more authors.. (1991) CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location.. Journal of immunology (Baltimore, Md. : 1950), (1): [PMID:1713603] |
| 6. Dariavach, P P, Mattéi, M G MG, Golstein, P P and Lefranc, M P MP.. (1988) Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains.. European journal of immunology, [PMID:3220103] |
| 7. Metzler, W J WJ and 10 more authors.. (1997) Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28.. Nature structural biology, [PMID:9228944] |
| 8. Marron, M P MP and 20 more authors.. (1997) Insulin-dependent diabetes mellitus (IDDM) is associated with CTLA4 polymorphisms in multiple ethnic groups.. Human molecular genetics, [PMID:9259273] |
| 9. Schneider, H H, Schwartzberg, P L PL and Rudd, C E CE.. (1998) Resting lymphocyte kinase (Rlk/Txk) phosphorylates the YVKM motif and regulates PI 3-kinase binding to T-cell antigen CTLA-4.. Biochemical and biophysical research communications, (9): [PMID:9813138] |
| 10. Djilali-Saiah, I I and 5 more authors.. (1998) CTLA-4 gene polymorphism is associated with predisposition to coeliac disease.. Gut, [PMID:10189842] |
| 11. Vaidya, B B and 6 more authors.. (1999) Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy.. Lancet (London, England), (28): [PMID:10475192] |
| 12. Ling, V V and 5 more authors.. (1999) Complete sequence determination of the mouse and human CTLA4 gene loci: cross-species DNA sequence similarity beyond exon borders.. Genomics, (15): [PMID:10493833] |
| 13. Chikuma, S S, Murakami, M M, Tanaka, K K and Uede, T T.. (2000) Janus kinase 2 is associated with a box 1-like motif and phosphorylates a critical tyrosine residue in the cytoplasmic region of cytotoxic T lymphocyte associated molecule-4.. Journal of cellular biochemistry, [PMID:10842319] |
| 14. Deng, Z Z and 11 more authors.. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.. American journal of human genetics, [PMID:10903931] |
| 15. Chistyakov, D A DA and 7 more authors.. (2000) Complex association analysis of graves disease using a set of polymorphic markers.. Molecular genetics and metabolism, [PMID:10924276] |
| 16. Schwartz, J C JC, Zhang, X X, Fedorov, A A AA, Nathenson, S G SG and Almo, S C SC.. (2001) Structural basis for co-stimulation by the human CTLA-4/B7-2 complex.. Nature, (29): [PMID:11279501] |
| 17. Stamper, C C CC and 9 more authors.. (2001) Crystal structure of the B7-1/CTLA-4 complex that inhibits human immune responses.. Nature, (29): [PMID:11279502] |
| 18. Ling, V V and 9 more authors.. (2001) Assembly and annotation of human chromosome 2q33 sequence containing the CD28, CTLA4, and ICOS gene cluster: analysis by computational, comparative, and microarray approaches.. Genomics, [PMID:11735222] |
| 19. Ueda, Hironori H and 52 more authors.. (2003) Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.. Nature, (29): [PMID:12724780] |
| 20. Barreto, Marta M and 12 more authors.. (2004) Evidence for CTLA4 as a susceptibility gene for systemic lupus erythematosus.. European journal of human genetics : EJHG, [PMID:15138458] |
| 21. Thio, Chloe L CL and 8 more authors.. (2004) Cytotoxic T-lymphocyte antigen 4 gene and recovery from hepatitis B virus infection.. Journal of virology, [PMID:15452244] |
| 22. Hunt, Karen A KA and 8 more authors.. (2005) A common CTLA4 haplotype associated with coeliac disease.. European journal of human genetics : EJHG, [PMID:15657618] |
| 23. Lee, Young Ho YH, Harley, John B JB and Nath, Swapan K SK.. (2005) CTLA-4 polymorphisms and systemic lupus erythematosus (SLE): a meta-analysis.. Human genetics, [PMID:15688186] |
| 24. Darlington, Peter J PJ, Kirchhof, Mark G MG, Criado, Gabriel G, Sondhi, Jitin J and Madrenas, Joaquín J.. (2005) Hierarchical regulation of CTLA-4 dimer-based lattice formation and its biological relevance for T cell inactivation.. Journal of immunology (Baltimore, Md. : 1950), (15): [PMID:16002699] |
| 25. Ribas, Antoni A and 8 more authors.. (2007) Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.. The oncologist, [PMID:17673618] |
| 26. Yang, James C JC and 12 more authors.. () Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis.. Journal of immunotherapy (Hagerstown, Md. : 1997), [PMID:18049334] |
| 27. Valk, Elke; Rudd, Christopher E and Schneider, Helga.. (2008) CTLA-4 trafficking and surface expression.. Trends in immunology, [PMID:18468488] |
| 28. Gu, Ming M and 6 more authors.. (2008) Identification of CTLA-4 isoforms produced by alternative splicing and their association with myasthenia gravis.. Clinical immunology (Orlando, Fla.), [PMID:18595775] |
| 29. Linsley, Peter S PS and Nadler, Steven G SG.. (2009) The clinical utility of inhibiting CD28-mediated costimulation.. Immunological reviews, [PMID:19426230] |
| 30. Yu, Chao and 11 more authors.. (2011) Rigid-body ligand recognition drives cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor triggering.. The Journal of biological chemistry, (25): [PMID:21156796] |
| 31. Kuehn, Hye Sun HS and 35 more authors.. (2014) Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4.. Science (New York, N.Y.), (26): [PMID:25213377] |
| 32. Schubert, Desirée D and 39 more authors.. (2014) Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.. Nature medicine, [PMID:25329329] |
